Industrial Biotechnology Corporation (PINKSHEETS: IBTY) (IBC), a company dedicated to new biotechnologies and innovations in the chemical industry, is honored to announce that Dr. Yuan-Chi Su (Professor Su) has accepted a position with IBC.
Dr. Su is currently an Emeritus Professor at National Taiwan University and a Committee Member on the Ministry of Economic Affairs, Biotechnology & Pharmaceutical Industries Program. He is also Chairman of Eatar Biotech Co., Ltd., Managing Director of the Taiwan Bio Industry Organization and credited with inventing Microbial Fermentation to Produce Glutamic Acid.
Throughout his career, Dr. Su has held numerous executive positions within the Asian biotechnology and chemical industry: President, Chinese Society of Microbiology; President, Bioindustry Development Association; President, Biomass Energy Society of China; Dean, National Taiwan University, College of Agriculture; President, Chinese Institute of Food Science and Technology; Chairman, National Taiwan University, Department of Agricultural Chemistry; President, Chinese Agricultural Chemical Society.
Dr. Su has been presented the following prestigious awards: Outstanding Performance in Technology Development Award (MOE, 1999), Outstanding Contribution Award of Prof. Steve Chang for Food Science and Technology (1994), Distinguished Professor Award (MOE, 1990), Applied Science and Technology Achievement Award (Executive Yuan, 1987), Outstanding Research Award (NSC, 1985-1996), Academic Achievement in Agricultural Science Award (MOE, 1986), Outstanding Invention Award (MOE, 1981), Food Science and Technology Achievement Award (CIFST, 1978), Sun Yet-Sen Academic Publication Award (1978), Academic Achievement Award (Chinese Agr. Chem. Soc., 1970) and Ten Outstanding Young Men Award (JCI, 1966). He received a Ph.D. and M.S. in Applied Microbiology from the University of Tokyo and B.S. in Agricultural Chemistry from National Taiwan University.
Professor Su will be assisting and overseeing the process development and scale up of targeted compounds prior to large scale production and manufacturing.
"We are pleased to have Dr. Su as a stakeholder of IBC and be directly involved with getting our targeted compounds ready for large scale production. Dr. Su will play a critical role for IBC by improving potency and yields of IBC compounds. We are truly honored to have him associated with IBC. He is another addition to our world-class science team that possesses the experience and know how of bio-process development and large scale commercial manufacturing of large magnitudes," said Andy Badolato, CEO of Industrial Biotechnology Corporation.
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) enables the biological production of chemicals through a combination of licensed patents, intellectual property and proprietary systems. We accomplish this through our ALCHEMx Productions Platforms(TM) which are a systematic, streamlined approach to biologically manufacture chemicals more efficiently, at significantly lower costs, and with substantially lower environmental impact than traditional methods. IBC and its partners plan to produce and market new and established biologically produced chemicals to the pharmaceutical, bio-energy, agricultural, biopesticides, fine chemicals, flavors and fragrances, cosmaceuticals, biomaterials and biopolymer industries. For more information about Industrial Biotechnology Corporation, please visit its website at www.industrialbiotechnology.com.
Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Industrial Biotechnology Corporation
2033 Main Street
Sarasota, FL 34237